Impacto do uso de corticoides a nível hospitalar na sobrevida de pacientes com COVID-19

Autores

  • Letícia Alves Rocha Imepac
  • Débora Vieira Imepac
  • Dayse Aparecida Rosa Vicente Imepac
  • Julliane Taynara Lourenço Borges
  • Luiz Geraldo de Souza Vargas Neto Imepac
  • Luiz Nunes de Azeredo Neto Imepac
  • Marluza Denone Picinalli Imepac
  • Iara Guimarães Rodrigues Imepac

DOI:

https://doi.org/10.47224/revistamaster.v7i14.297

Palavras-chave:

SARS-COV-2, Corticosteroides, Dexametasona, Hidrocortisona, Prednisolona×

Resumo

Diante das controvérsias existentes atualmente a respeito do tratamento de pacientes hospitalizados com COVID-19,
faz-se necessário a análise de artigos a respeito do uso de corticoides para determinar se os riscos dessa terapia
superam seus benefícios. No Brasil foi identificada maior incidência no Mato Grosso e Rio de Janeiro, com total
confirmado de mais de 25 milhões e letalidade em torno de 2,5%. O presente estudo foi desenvolvido a fim de realizar
um levantamento da literatura e verificar as opções medicamentosas mais utilizadas frente sua eficácia. Foi
identificado o uso clínico de corticosteroides, os quais se demonstraram não tão eficazes, porém necessários e carecem
acompanhamento clínico para avaliar o risco e benefício. Ensaios clínicos controlados randomizados de administração
precoce de uma dose baixa a moderada de metilprednisolona para pacientes com COVID-19 com SDRA são necessários
para confirmar a eficácia e segurança da terapia com corticosteroides e estudar mais os resultados a longo prazo após
a alta.

Downloads

Não há dados estatísticos.

Referências

ARABI, Y. M., et al., Corticosteroid therapy for critically ill patients with Middle East respiratory

syndrome. American journal of respiratory and critical care medicine, v.197, n.6, p.757-767, 2018.

BAI, C, et al. [Updated guidance on the management of COVID-19: from an American Thoracic

Society/European Respiratory Society coordinated International Task Force. European Respiratory Review

[Internet]. v.29, n.157, p.1-15, 2020.

Bhimraj, et al. Infectious Diseases Society of America Guidelines on the treatment and management of

patients with coronavirus disease 2019 (COVID-19). Clinical Infectious Diseases, ciaa478, 2020.

Braz-de-Melo HA, et al. The Use of the Anticoagulant Heparin and Corticosteroid Dexamethasone as

Prominent Treatments for COVID-19. Frontiers in Medicine. v.8, p.615333, 2021.

CALY, L, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral

Research. v.178, p.104787, 2020.

CÂMARA, FP, CARDOSO, D, CÂMARA, P, MORENO, M. Contágio e virulência: covid-19 e a próxima pandemia.

Brazilian Journal of Health Review. v.3, n5, p.3353-7, 2020.

CAVALCANTI, AB, et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. New

England Journal of Medicine, v.383, n.21, p.2041-52, 2020.

BRASIL. Coronavírus Brasil. Painel Coronavírus. 2022. [Internet]. Disponível em: https://covid.saude.gov.br/

DEQUIN, P. F., et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill

patients with COVID-19: a randomized clinical trial. Jama, v.324, n.13, 1298-1306, 2020.

Edalatifard, M., Akhtari, M. et al. Intravenous methylprednisolone pulse as a treatment for hospitalised

severe COVID-19 patients: results from a randomised controlled clinical trial. European Respiratory

Journal, v.56, n.6, 2020.

Fadel, et al. Early short-course corticosteroids in hospitalized patients with COVID-19. Clinical Infectious

Diseases, v.71, n.16, p.2114-2120, 2020.

FAQ COVID-19 DA SBI – Sociedade Brasileira de Imunologia. 2022 [Internet]. Disponível em:

https://sbi.org.br/2021/03/16/faq-covid-19-da-sbi-2/

Gautret, P., et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label

non-randomized clinical trial. International journal of antimicrobial agents, v.56, n.1, p.105949, 2020.

GROUP RC, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. The New

England Journal of Medicine. v.384, n.8, p.693–704, 2020.

GUAN, Wei-jie et al. Clinical characteristics of coronavirus disease 2019 in China. New England journal of

medicine, v. 382, n. 18, p. 1708-1720, 2020.

HUANG, Chaolin et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The

lancet, v. 395, n. 10223, p. 497-506, 2020.

Jeronimo, C. M. P., et al. Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus

disease 2019 (COVID-19; Metcovid): a randomized, double-blind, phase IIb, placebo-controlled trial. Clinical

Infectious Diseases, v.72, n.9, p.e373-e381, 2021.

KO, JJ, et al. A Comparison of Methylprednisolone and Dexamethasone in Intensive Care Patients With COVID.

Journal of Intensive Care Medicine, v.36, n.6, p.673-80, 2021.

LI, Huan et al. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERSCoV infection: a systematic review and meta-analysis. Leukemia, v. 34, n. 6, p. 1503-1511, 2020.

MASKIN, L. P., et al. High dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary

to COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials, v.21, n.1,

p.1-3, 2020.

MINA, M. J., PARKER, R., LARREMORE, D. B. Rethinking Covid-19 test sensitivity—a strategy for

containment. New England Journal of Medicine, v.22, n.383, e120, 2020.

Moreno, G., et al. Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a

propensity score matching study. Intensive care medicine, v.44, n.9, p.1470-1482, 2018.

PEERI, N. C, et al.. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest

global health threats: what lessons have we learned? International journal of epidemiology, v.3, n.49,p.

-726, 2020.

Petersen, M. W., et al., Low‐dose hydrocortisone in patients with COVID‐19 and severe hypoxia (COVID

STEROID) trial-protocol and statistical analysis plan. Acta Anaesthesiologica Scandinavica, v.64, n.9, p.1365-

, 2020.

Pinzón MA, et al. Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia. PLOS ONE, v.16,

n.5, p.e0252057, 2021.

Ranjbar K., et al. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment

of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. BMC Infectious Diseases,

v.21, n.1, p.1–8, 2021.

Rosas, I. O., et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal

of Medicine, v.384, n.16, 1503-1516, 2021.

SIDDELL, S. G. et al. Coronaviridae. Intervirology, v. 20, n. 4, p. 181-189, 1983.

SILVA, Daylane Fernandes; DE OLIVEIRA, Maria Liz Cunha. Epidemiologia da COVID-19: comparação entre

boletins epidemiológicos. Comunicação Em Ciências Da Saúde, v. 31, p. 61-74, 2020.

Sterne, J. A. et al. Corticosteroid therapy for critically ill patients with COVID-19: A structured summary of a

study protocol for a prospective meta-analysis of randomized trials. Trials, v.21, n.1, p.1-3, 2020

Tomazini BM, et al. COVID-19-associated ARDS treated with DEXamethasone (CoDEX): study design and

rationale for a randomized trial. Revista Brasileira de Terapia Intensiva, v.32, n.3, p.354–62, 2020.

VILLAR, J., et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre,

randomised controlled trial. The Lancet Respiratory Medicine, v.8, n.3, p.267–76, 2020.

WILLIAMS, D. M. Clinical pharmacology of corticosteroids. Respiratory care, v.63, n.6, p.655-670, 2018

Downloads

Publicado

2022-12-31

Como Citar

ALVES ROCHA, L.; VIEIRA, D. .; APARECIDA ROSA VICENTE, D.; TAYNARA LOURENÇO BORGES, J. .; GERALDO DE SOUZA VARGAS NETO, L.; NUNES DE AZEREDO NETO, L. .; DENONE PICINALLI, M. .; GUIMARÃES RODRIGUES, I. . Impacto do uso de corticoides a nível hospitalar na sobrevida de pacientes com COVID-19. Revista Master - Ensino, Pesquisa e Extensão, [S. l.], v. 7, n. 14, 2022. DOI: 10.47224/revistamaster.v7i14.297. Disponível em: https://revistamaster.imepac.edu.br/RM/article/view/297. Acesso em: 18 abr. 2024.

Artigos mais lidos pelo mesmo(s) autor(es)